The presence of both γδ T cells and MAIT cells in the treatment group indicates a potential coordinated involvement of these immune cell types in the anti-cancer immune response triggered by the lenvatinib plus anti-PD1 antibody treatment in HCC [70]. Here, PDCD1 is linked to hepatocellular carcinoma.